Pricing Log in Create free account
Monday 2 November 2026 Export TWST’s income statement to Excel — free account

Twist Bioscience Corporation

TWST Healthcare Biotechnology

Twist Bioscience Corporation’s revenue for fiscal 2025 (year ended September 2025) was $376.6 million, up 20.3% from fiscal 2024.

Revenue
+23.2%
EPS
−264.7%
Free cash flow
−7.23%
Total debt
0.00%

Quarter to June 2026, against a year earlier

129.86 22.92 −15.00%
Market cap
$10.1B
P/E
0.0×
Fwd P/E
−91.4×
Dividend yield
—
F-score
4/9
Altman Z
3.44
Beneish M
−2.30
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Filings

Insider Decisions last twelve months

Sold, $m 146.50
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell 7 4 18 8 7 20 10 2 19 9 9 —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Size
Market Cap 10,060.00
Revenue ttm 431.80
Net income ttm (136.72)
Free cash flow ttm (95.62)
Net debt Q (151.84)
Valuation
P/E 0.00
Forward P/E (91.40) (negative: loss-making)
Price / sales 22.08 (above 10: high)
Forward P/S Powerpack
Price / FCF 0.00
Price / book 21.39 (above 6: high)
Financial health
Current ratio Q 2.67 (at or above 1.5: strong)
Debt / equity Q 0.03 (at or below 0.5: strong)
Interest coverage Q (290.63)
Growth
Revenue growth Q +23.24% (above 0%: growing)
Operating income growth Q −20.45% (below 0%: shrinking)
EPS, this year −64.76% (below 0%: weak)
EPS, next year A +38.79% (at or above 15%: strong)
Revenue, next year A +21.17% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +12.43%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 21.7×, against a ten-year median of 9.5×; over the ten years it ranged from −1.1× in 2018 to 69.1× in 2021.
P/S against its own 10 years 78.66%
10-year low 10-year high
P/B against its own 10 years 98.98%
10-year low 10-year high
EV/Sales against its own 10 years 79.67%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 336 276 232 167
Receivables 44 35 57 65
Inventory 32 24 28 35
Other — — — —
424 347 333 321
2023 2024 2025 Q'26
Payables 14 2 11 17
ST’ Debt — — — —
Other 8 6 12 —
73 71 91 120

Compound Annual Growth %

10y 5y 3y
Sales — 33.11% 22.76%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 7.06% (15.70%)

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate −0.50 Actual −0.56

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 −0.40 −0.45 Miss by 0.05
Q1 FY26 −0.48 −0.50 Miss by 0.02
Q2 FY26 −0.54 −0.62 Miss by 0.08
Q3 FY26 −0.50 −0.56 Miss by 0.06
Q4 FY26 −0.44 — Reports 12 November 2026

EPS $

Dec Mar Jun Sep Year
’26 (0.50) (0.71) (0.56) — —
’25 (0.53) (0.66) 0.33 (0.45) (1.30)
’24 (0.75) (0.79) (1.47) (0.59) (3.60)
’23 (0.74) (1.04) (1.01) (0.81) (3.60)
’22 (0.91) (1.13) (1.08) (0.91) (4.04)
’21 (0.72) (0.78) (0.82) (0.84) (3.15)
’20 (1.69) (0.85) (0.67) (0.54) (3.57)
Fiscal quarters ending in the months shown.

Revenue $m

Dec Mar Jun Sep Year
’26 104 111 118 — —
’25 89 93 96 99 377
’24 71 75 81 85 313
’23 54 60 64 67 245
’22 42 48 56 57 204
’21 28 31 35 38 132
’20 17 19 21 32 90
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Dec Mar Jun Sep Year
’26 (25) (18) 1 — —
’25 (21) (13) (1) (12) (48)
’24 (23) (19) (6) (15) (64)
’23 (54) (44) (23) (21) (142)
’22 (47) (42) (34) (1) (124)
’21 (25) (25) (28) (35) (112)
’20 (35) (59) (23) (25) (142)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Dec Mar Jun Sep Year
’26 (35) (26) (9) — —
’25 (24) (17) (8) (27) (76)
’24 (24) (20) (7) (17) (69)
’23 (66) (53) (28) (23) (170)
’22 (59) (74) (75) (18) (226)
’21 (29) (33) (35) (43) (139)
’20 (37) (61) (26) (27) (152)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.9
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to September

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 2 11 25 54 90 132 204 245 313 377 432 +76.5% 456 549 646 +19.7%
Gross margin, % (315.20) (123.09) (26.59) 12.80 31.85 39.08 41.38 36.61 42.61 50.72 51.97 +365.9 pt
EBT (44) (59) (71) (107) (140) (154) (228) (203) (208) (77) (136) +6.4%
EBT margin, % (1,943.06) (548.25) (279.21) (197.44) (154.88) (116.39) (112.14) (83.01) (66.51) (20.43) (31.46) +1,922.6 pt
Net income (44) (59) (71) (108) (140) (152) (218) (205) (209) (78) (137) +6.5%
Per share, $
Per share, $ Revenue 1.21 4.45 9.10 1.98 2.30 2.74 3.78 4.31 5.39 6.30 6.92 +20.1%
Earnings (23.58) (24.49) (25.51) (3.92) (3.57) (3.15) (4.04) (3.60) (3.60) (1.30) (2.22) (27.5%)
Cash flow (20.64) (21.18) (23.69) (3.20) (3.63) (2.33) (2.31) (2.50) (1.10) (0.80) (0.85) (30.3%)
Capex (3.33) (2.61) (1.31) (0.54) (0.25) (0.56) (1.89) (0.49) (0.09) (0.47) (0.68) (19.6%)
Free cash flow (23.97) (23.79) (25.00) (3.74) (3.88) (2.89) (4.20) (2.99) (1.19) (1.26) (1.53) (27.9%)
Book value 0.00 27.36 31.89 5.54 8.58 12.04 14.65 10.96 8.15 7.91 7.14 n/m
Shares, m 2 2 3 27 39 48 54 57 58 60 61 +47.0%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S 1.66 1.66 1.66 12.06 33.04 39.00 9.33 4.45 8.38 4.47 22.08 11.6
P/B 0.00 0.00 0.00 4.31 8.85 8.89 2.41 1.75 5.55 3.56 21.39 3.5
EV/Sales (1.13) (1.13) (1.13) 9.66 29.88 35.80 7.25 3.41 7.75 3.90 21.73 9.4
EV/FCF 0.41 0.41 0.41 (5.12) (17.70) (34.01) (6.53) (4.90) (35.07) (19.40) (98.13) (12.1)
Cash, $m
Cash, $m Operating cash flow (39) (51) (66) (88) (142) (112) (124) (142) (64) (48) (53) +2.4%
Capex (6) (6) (4) (15) (10) (27) (102) (28) (5) (28) (43) +18.2%
Free cash flow (45) (58) (70) (103) (152) (139) (226) (170) (69) (76) (96) +6.0%
Balance, $m
Balance, $m Working capital 50 58 77 130 299 483 506 351 276 242 201 +19.0%
Net debt (45) (53) (71) (130) (285) (423) (424) (257) (276) (217) (152) +19.2%
Shareholders’ equity — 66 89 152 336 581 789 623 473 473 446 +27.8%
Returns, %
Returns, % ROA (102.94) (138.48) (70.72) (71.12) (47.77) (27.63) (26.19) (23.55) (30.02) (12.37) (20.78) +90.6 pt
ROIC 0.00 (276.38) (244.70) (313.39) (171.68) (60.54) (40.13) (37.06) (70.31) (33.33) (30.83) (33.3) pt
ROE 41.99 56.49 42.56 436.44 (57.31) (33.17) (31.80) (28.97) (38.08) (16.43) (29.59) (58.4) pt
People
People Employees — 221 289 414 525 652 989 919 923 979 — +20.4%
Revenue/emp, $m 0.00 0.05 0.09 0.13 0.17 0.20 0.21 0.27 0.34 0.38 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Sep 2025 · latest quarter Jun 2026

Business profile

Updated

Twist Bioscience makes synthetic DNA and related tools for customers working in healthcare, industrial materials, agriculture and academic research. Its chief executive officer is Emily M. Leproust, Ph.D. The company’s platform uses silicon chips to manufacture DNA sequences designed by customers. Those sequences give researchers material they can use to test biological ideas, develop products and study disease.

Its synthetic biology products include genes, gene fragments and pools of short DNA sequences called oligonucleotides. Customers can order custom sequences in different lengths and configurations. For example, a drug developer may order variations of a gene to find a sequence that meets its research objective.

Twist Bioscience Corporation vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
JAZZ Jazz Pharmaceuticals PLC $14.0B 14.2× 35.9× +15.55% (above 0%: growing) n/m +140.99% (above 0%: growing) 90.37% 20.54% Compare
SMMT Summit Therapeutics PLC $12.8B — (loss-making) — (loss-making) −100.00% (below 0%: shrinking) n/m −112.80% (below 0%: shrinking) 0.00% 0.00% Compare
TECH Bio-Techne Corp $11.4B 62.1× 54.2× +1.33% (above 0%: growing) n/m −6.83% (below 0%: shrinking) 65.82% 23.13% Compare
BMRN BioMarin Pharmaceutical Inc. $11.3B 154× 32.7× +19.91% (above 0%: growing) −81.60% (below 0%: shrinking) −20.28% (below 0%: shrinking) 79.51% 11.21% Compare
KYMR Kymera Therapeutics, Inc. $10.8B — (loss-making) — (loss-making) +466.40% (above 0%: growing) n/m +9.97% (above 0%: growing) 100.00% (116.32%) Compare
TWST Twist Bioscience Corporation $10.1B — (loss-making) — (loss-making) +23.24% (above 0%: growing) n/m −7.23% (below 0%: shrinking) 52.76% (30.65%)
MDGL Madrigal Pharmaceuticals, Inc. $9.9B — (loss-making) — (loss-making) +71.17% (above 0%: growing) n/m +140.54% (above 0%: growing) 89.02% (15.46%) Compare
PCVX Vaxcyte, Inc. $9.8B — (loss-making) — — n/m −92.55% (below 0%: shrinking) 0.00% 0.00% Compare
CAI Caris Life Sciences,�Inc. $9.7B 91.3× 254× +45.38% (above 0%: growing) n/m +8.47% (above 0%: growing) 68.10% 10.21% Compare
Median of peers $11.1B 76.7× 45.1× +19.91% — +0.82% 73.81% 5.11%

All 619 Biotechnology stocks →

From the latest earnings call

Updated

  • CEO Emily Leproust said repeat orders and new customers were supporting demand for AI-enabled drug discovery, with customers increasingly sharing their future needs.
  • CFO Adam Laponis said Twist expected lower operating expenses in the fourth quarter and remained committed to reaching adjusted EBITDA breakeven.

Largest institutional holders 13F, quarter to 30 June 2026

Held by institutions 120.00%
Held by the ten largest 64.24%
Holder Shares Stake Change
Vanguard 6.07m 9.69% +261.42k
BlackRock 5.83m 9.31% +279.53k
Artisan Partners Limited Partnership 4.80m 7.66% −1.57m
Fidelity (FMR) 4.70m 7.50% +2.81m
ARK Investment Management LLC 4.55m 7.26% −1.79m
T. Rowe Price 4.23m 6.75% +4.16m
State Street 3.23m 5.16% −438.15k
EdgePoint Investment Group Inc. 2.52m 4.02% −2.86m
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC 2.17m 3.47% −3.10m
FARALLON CAPITAL MANAGEMENT, L.L.C. 2.14m 3.41% +708.75k
13F filings for the quarter to 30 June 2026: long positions in US-listed shares reported by managers with $100m or more, ~45 days after the quarter.

Pay and ownership Proxy statement filed 6 January 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 13.78m 928.13k 37.04
2024 7.62m 24.98m 59.47
2023 8.00m 3.22m 26.67
2022 5.92m (15.04m) 46.39
2021 1.28m 18.05m 140.81

Ownership

Directors and executive officers, together 3.08%
Artisan Partners Limited Partnership 10.48%
ARK Investment Management LLC 10.43%
The Vanguard Group 8.95%
BlackRock, Inc. 8.05%
EdgePoint Investment Group Inc. 6.67%
William Blair Investment Management, LLC 6.22%
State Street Corporation 5.05%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Twist Bioscience Corporation (TWST) Latest News

29 Oct

Impact 4 · · Insider Monkey
Impact 4 · · Business Wire
Impact 4 · · Simply Wall St.

28 Oct

Impact 4 · · Business Wire

27 Oct

Impact 4 · · Insider Monkey

26 Oct

Impact 3 · · Business Wire

23 Oct

Impact 4 · · Insider Monkey

22 Oct

Impact 4 · · TIKR

5 Oct

Impact 4 · · Stocktwits

2 Oct

Impact 3 · · Simply Wall St.
Impact 3 · · Simply Wall St.

26 Sep

Impact 3 · · Insider Monkey

25 Sep

Impact 4 · · Trefis
Impact 4 · · TIKR

22 Sep

Impact 4 · · Insider Monkey

21 Sep

Impact 3 · · Barchart

18 Sep

Impact 4 · · The Motley Fool

17 Sep

Impact 4 ·
Impact 3 · · Stocktwits

16 Sep

Impact 4 ·
Impact 3 ·

8 Sep

Impact 4 ·

10 Aug

Impact 3 · · The Motley Fool transcript

8 Aug

Impact 4 ·

7 Aug

Impact 4 ·

4 Aug

Impact 3 ·
Impact 3 ·
Impact 3 · · Moby transcript

3 Aug

Impact 4 ·
Impact 3 · · MarketBeat transcript
stockrow.com/TWST · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com